Tumor type M<sub>2</sub>pyruvate kinase expression in gastric cancer, colorectal cancer and controls

Zhang, Bo; Chen, Jianying; Daoda, Chen; Wang, Guobin; Shen, Ping

doi:10.3748/wjg.v10.i11.1643

Cited by 57 publications

(37 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The serum level of tumor M2-PK among normal people should be low compared to that among colorectal lesion patients and should not vary by gender and age. The average level of serum M2-PK among 158 normal people was 2.96 U/mL which is much lower than those in clinical patients or volunteers [22,23] . Our community-based results for serum levels of M2-PK associated with the TNM Classification of Malignant Tumors and Duke's staging in CRC are supported by these patient-based clinical studies [22,23] .…”

Section: Discussionmentioning

confidence: 99%

“…The average level of serum M2-PK among 158 normal people was 2.96 U/mL which is much lower than those in clinical patients or volunteers [22,23] . Our community-based results for serum levels of M2-PK associated with the TNM Classification of Malignant Tumors and Duke's staging in CRC are supported by these patient-based clinical studies [22,23] . Because our result for normal serum level of M2-PK was based on a large sample size (158) from communities in a CRC mass screening program, it is reliable and can be generalizable.…”

Section: Discussionmentioning

confidence: 99%

“…Blood tests are more convenient than fecal tests and can achieve a higher compliance rate in the general population. Clinical studies indicate that serum M2-PK has a higher sensitivity than serum carcinoembryonic antigen (CEA), is a valuable tumor marker in detection of gastrointestinal cancer [22,23] and has advantages in finding localized CRC [24] . No study has investigated the value of serum M2-PK in CRC mass screening in a community setting.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Meng¹,

Zhu

Xu³

et al. 2012

WJGO

View full text Add to dashboard Cite

Author contributions: Meng W and Zhu HH contributed equally to this work; Meng W conducted the study, data collection, management and analysis, and drafted the manuscript; Zhu HH did data correction, designed the analysis strategy and did data interpretation, co-drafted and revised the manuscript, reviewed and edited the whole manuscript; Xu ZF performed quality control on ELISA work; Cai SR performed previous screening work and collection of serum samples; Dong Q performed helpful work in previous screening; Pan QR did part of ELISA work; Zheng S co-supervised the field activities and designed the study's analytical strategy; Zhang SZ co-designed the study, co-supervised the field activities and did quality assurance and control. METHODS:We conducted a molecular epidemiology study in Hangzhou, China, from year 2006 to year 2008. Serum samples were collected from 93 CRC, 41 advanced adenomas, 137 adenomas, 47 non-adenomatous polyps, and 158 normal participants in a community setting. Serum M2-PK and carcinoembryonic antigen (CEA) were measured using Enzyme-linked immunosorbent assay. SPSS 16.0 software was used to perform data analysis. Area under the receiver operating characteristic curve (AUC), sensitivity, and specificities were estimated for serum M2-PK in diagnosis of colorectal lesions and compared with CEA. RESULTS:Average serum M2-PK value among 158 normal people was 2.96 U/mL and not affected by gender (P = 0.47) or age (P = 0.59). Average serum M2-PK (U/mL) was 14.75 among stage Ⅲ and 13.10 among stage Ⅰ and Ⅱ CRC patients, about 4 times higher than that among normal people. Average serum M2-PK was 8.58, 6.70, 5.13 and 2.51 U/mL among advanced adenoma, adenomas, non-adenomatous polyps, and inflammatory bowel disease patients, respectively. AUC for serum M2-PK was greater than that for CEA among all colorectal lesions. AUC for serum M2-PK was 0.89 (0.84, 0.94) (95% confidence interval), higher than that for CEA [0.70 (0.62-0.79 The diagnostic sensitivity for all colorectal lesions increased with decrease in the cut-off value of serum M2-PK. The diagnostic sensitivity (%) of serum M2-PK was 100.00 for CRC, 95.12 advanced adenoma, 82.48 adenoma, and 82.98 non-adenomatous polyp. There were no CRC cases missed and 40.51% of BRIEF ARTICLE

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Meng¹,

Zhu

Xu³

et al. 2012

WJGO

View full text Add to dashboard Cite

show abstract

“…Moreover, serum ENO2 is considered to be a prognostic factor in small cell lung, breast, and prostrate cancer (36)(37)(38)(39). Finally, PKM2 seems to be a more sensitive marker than conventional tumor markers such as CEA and CA72-4 for the post-operative surveillance of gastrointestinal cancer (40)(41)(42)(43)(44).…”

Section: Discussionmentioning

confidence: 99%

Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers

Yeh

Wang²,

Chung³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

Abstract. We investigated gene expressions involved in the glycolytic pathways in colorectal cancer. The study was designed to use gene ontology and its relevant bioinformatics tools to analyze the microarray data obtained from CRC tissues and their corresponding normal tissues, in order to explore the correlation between the glycolytic metabolic pathway and possible pathogenesis of this disease. The overexpression of glycolysis-related genes was observed in over 76% of CRC tissues. In addition, we stimulated the SW480 and SW620 CRC cell lines with 15 mM D-(+)-glucose and 10 mM 2-deoxy-D-glucose respectively. The results indicate that the proliferation response of both the SW480 and SW620 cell lines increased remarkably with a time-dependent effect by D-(+)-glucose administration. In contrast, the proliferation response of both the SW480 and SW620 cell lines was significantly inhibited by 2-DG administration. Likewise, further analyses of the expression of related genes triggered by the D-(+)-glucose in vivo show that the activation process of these eight genes -GLUT1, HK1, GPI, GAPD, PGK1, PGK2, ENO2, PKM2 -prominently increased with a timedependent effect. In conclusion, this study demonstrates that the glycolytic pathway and glycolysis-related genes may play an important role in the tumorigenesis of CRC, but their molecular mechanisms need further investigation to verify this.

show abstract

“…In addition, two independent studies revealed that the use of M2-pyruvate kinase for the detection of CRC has a sensitivity of 48-58% and a specificity of 90-95%. Furthermore, when combined with CEA, the sensitivity of M2-pyruvate increases without decreasing the specificity (58,59).…”

Section: M2-pyruvate Kinasementioning

confidence: 99%

Noninvasive molecular biomarkers for the detection of colorectal cancer

Kim¹,

Yu²,

Kim³

et al. 2008

BMB Reports

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common malignancy in the world. Because CRC develops slowly from removable precancerous lesions, detection of the disease at an early stage during regular health examinations can reduce both the incidence and mortality of the disease. Although sigmoidoscopy offers significant improvements in the detection rate of CRC, its diagnostic value is limited by its high costs and inconvenience. Therefore, there is a compelling need for the identification of noninvasive biomarkers that can enable earlier detection of CRC. Accordingly, many validation studies have been conducted to evaluate genetic, epigenetic or protein markers that can be detected in the stool or in serum. Currently, the fecal-occult blood test is the most widely used method of screening for CRC. However, advances in genomics and proteomics combined with developments in other relevant fields will lead to the discovery of novel non invasive biomarkers whose usefulness will be tested in larger validation studies. Here, noninvasive molecular biomarkers that are currently used in clinical settings and have the potential for use as CRC biomarkers are discussed. [BMB reports 2008; 41(10): 685-692]

show abstract

Tumor type M₂pyruvate kinase expression in gastric cancer, colorectal cancer and controls

Abstract: Tumor M(2)-PK has a higher sensitivity than markers CEA and CA72-4, and is a valuable tumor marker for the detection of gastrointestinal cancer.

Cited by 57 publications

References 12 publications

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers

Noninvasive molecular biomarkers for the detection of colorectal cancer

Contact Info

Product

Resources

About

Tumor type M2pyruvate kinase expression in gastric cancer, colorectal cancer and controls

Abstract: Tumor M(2)-PK has a higher sensitivity than markers CEA and CA72-4, and is a valuable tumor marker for the detection of gastrointestinal cancer.

Cited by 57 publications

References 12 publications

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers

Noninvasive molecular biomarkers for the detection of colorectal cancer

Contact Info

Product

Resources

About

Tumor type M₂pyruvate kinase expression in gastric cancer, colorectal cancer and controls